Francesco Cognetti
Overview
Explore the profile of Francesco Cognetti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
272
Citations
8830
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cardone A, Bell D, Biurrun C, Cognetti F, Cardoso F, Piris A, et al.
Breast
. 2025 Mar;
81:104436.
PMID: 40058335
Purpose: Genomic testing, involving expression profiling of tumour tissue, is a powerful tool for determining appropriate treatments for certain cancer patients. This study aimed to evaluate awareness of genomic testing...
2.
Molinelli C, Bruzzone M, Blondeaux E, Ruelle T, Lanzavecchia C, De Laurentiis M, et al.
Eur J Cancer
. 2024 Nov;
213():115113.
PMID: 39536433
Purpose: The aim of this study was to evaluate the effectiveness of CDK 4/6 inhibitors (CDK 4-6i) according to HER2 status (low/zero), and endocrine resistance/sensitivity, as well as the efficacy...
3.
Cazzaniga M, Pronzato P, Amoroso D, Bernardo A, Biganzoli L, Bisagni G, et al.
Cancers (Basel)
. 2024 Jan;
16(1).
PMID: 38201545
GIM 13-AMBRA is a longitudinal cohort study aimed at describing therapeutic strategies and the relative outcome parameters in 939 HER2-ve MBC patients. Taxanes-based regimens, or taxanes + targeted agents, mainly...
4.
Ascierto P, Di Giacomo A, Sileni V, Queirolo P, Spagnolo F, De Galitiis F, et al.
Eur J Cancer
. 2023 Aug;
191:113246.
PMID: 37549531
Introduction: The CheckMate 238 randomised study demonstrated the relevant benefit in terms of recurrence-free survival (RFS) of nivolumab versus ipilimumab in resected stage IIIB-C or IV melanoma patients with a...
5.
Del Mastro L, Poggio F, Blondeaux E, De Placido S, Giuliano M, Forestieri V, et al.
Lancet Oncol
. 2022 Nov;
23(12):1571-1582.
PMID: 36370716
Background: Previous analyses of the GIM (Gruppo Italiano Mammella) 2 study showed that addition of fluorouracil to epirubicin, cyclophosphamide, and paclitaxel in patients with node-positive early breast cancer does not...
6.
Fabi A, Fotia L, Giuseppini F, Gaeta A, Falcicchio C, Giuliani G, et al.
Front Oncol
. 2022 Oct;
12:960387.
PMID: 36249001
Background: A virtual reality experience (VRE) could represent a viable non-pharmacological intervention to reduce and better manage the main factors of psychophysical distress related to the diagnosis and treatment of...
7.
Di Noia V, Pimpinelli F, Renna D, Campo F, Cosimati A, Torchia A, et al.
Eur J Cancer
. 2022 Oct;
176:164-167.
PMID: 36223679
No abstract available.
8.
Cicini M, Ferretti G, Morace N, Nistico C, Cognetti F, Rulli F
Breast Care (Basel)
. 2022 Aug;
17(3):330-335.
PMID: 35957944
Introduction: A wide spectrum of cardiovascular (CV) toxicity is associated with anticancer treatment, and nearly all chemotherapeutic agents can elicit CV toxicity. Inhibitors of cyclin-dependent kinases 4/6 (CDK4/6Is) have become...
9.
Barberi V, Renna D, Annovazzi A, Ferretti G, Russillo M, Cognetti F
Recenti Prog Med
. 2022 Jun;
113(6):376-379.
PMID: 35758116
Breast cancer is still the leading cause of cancer-related deaths among women aged 20-59 and metastatic breast cancer remains an incurable disease. The therapeutic paradigm of patients with HR-positive HER2-negative...
10.
Conciatori F, Salvati E, Ciuffreda L, Shirasawa S, Falcone I, Cognetti F, et al.
Front Oncol
. 2022 Jun;
12:862806.
PMID: 35719951
Purpose: Tumor-microenvironment interactions are important determinants of drug resistance in colorectal cancer (CRC). We, therefore, set out to understand how interactions between genetically characterized CRC cells and stromal fibroblasts might...